DERMASTRAT Trademark

Trademark Overview


On Friday, June 14, 2013, a trademark application was filed for DERMASTRAT with the United States Patent and Trademark Office. The USPTO has given the DERMASTRAT trademark a serial number of 85960339. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 31, 2023. This trademark is owned by Randox Laboratories Ltd. The DERMASTRAT trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for the treatment of psoriasis, and pharmaceutical substances, namely, for the prediction of response to anti-Tumor Necrosis Factor, also known as TNF, therapies and sanitary preparations for the prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic preparations and substances for medical use; diagnostic kits consisting primarily of multiplex polymerase chain reaction reagents and biochip array reagents; clinical diagnostic preparations for medical use; clinical diagnostic reagents for medical in vitro and/or vivo use; diagnostic scanning agents for in-vivo use used for the prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic testing materials, namely, diagnostic preparations, reagents and contrast media for medical use; clinical medical reagents; reagents for use in diagnostic tests for medical purposes; reagents for use with analyzers for medical purposes; parts and fittings for all the aforesaid goods, namely, mu...

Chemicals used in industry, science, photography, agriculture, horticulture and forestry; chemical reagents other than for medical purpose; enzymes for scientific and research purposes and proteins for industrial use; diagnostic preparations for scientific purposes; clinical diagnostic preparations or reagents other than for medical use; diagnostic preparations, namely, diagnostic scanning agents; diagnostic testing materials, namely, diagnostic preparations, reagents and contrast media other than for medical use; chemical reagents for use in diagnostic tests, other than for medical use; clinical diagnostic reagents for laboratory in vitro and/or vivo use

Medical services; providing health advice and information services; medical care services; health clinic services; healthcare services, namely, geriatric health care, physical therapy; medical health assessment services, namely, providing prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic health screening services in the field of psoriasis; medical testing for prediction of response to therapy; medical diagnostic testing services; genetic testing for medical for medical purposes; medical clinics; advice, information and consultancy services for all of the aforesaid services

Scientific and technological services, namely, research and design in the field of psoriasis; medical research services; clinical research services, namely, conducting clinical trials for others; biological research; conducting clinical trials for others, namely, analysis, management and reporting of clinical data; consulting services in the field of quality assessment services for clinical laboratories; chemical research; chemical laboratory services; chemical analysis; scientific and medical laboratory services for analytical testing; medical laboratory services; biochemistry research and consultant advisory services; conducting clinical trials for others; providing computer aided diagnostic testing services for predicting response to anti-Tumor Necrosis Factor therapies for others in the field of science and research related thereto; scientific and technological services, namely, development of test equipment for medical apparatus for others; advice, information and consultancy serv...
dermastrat

General Information


Serial Number85960339
Word MarkDERMASTRAT
Filing DateFriday, June 14, 2013
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 31, 2023
Registration Number5043491
Registration DateTuesday, September 20, 2016
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 25, 2014

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of psoriasis, and pharmaceutical substances, namely, for the prediction of response to anti-Tumor Necrosis Factor, also known as TNF, therapies and sanitary preparations for the prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic preparations and substances for medical use; diagnostic kits consisting primarily of multiplex polymerase chain reaction reagents and biochip array reagents; clinical diagnostic preparations for medical use; clinical diagnostic reagents for medical in vitro and/or vivo use; diagnostic scanning agents for in-vivo use used for the prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic testing materials, namely, diagnostic preparations, reagents and contrast media for medical use; clinical medical reagents; reagents for use in diagnostic tests for medical purposes; reagents for use with analyzers for medical purposes; parts and fittings for all the aforesaid goods, namely, multiplex polymerase chain reaction reagents and biochip array reagents; chemical reagents for medical purposes; enzymes for medical purposes
Goods and ServicesChemicals used in industry, science, photography, agriculture, horticulture and forestry; chemical reagents other than for medical purpose; enzymes for scientific and research purposes and proteins for industrial use; diagnostic preparations for scientific purposes; clinical diagnostic preparations or reagents other than for medical use; diagnostic preparations, namely, diagnostic scanning agents; diagnostic testing materials, namely, diagnostic preparations, reagents and contrast media other than for medical use; chemical reagents for use in diagnostic tests, other than for medical use; clinical diagnostic reagents for laboratory in vitro and/or vivo use
Goods and ServicesMedical services; providing health advice and information services; medical care services; health clinic services; healthcare services, namely, geriatric health care, physical therapy; medical health assessment services, namely, providing prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic health screening services in the field of psoriasis; medical testing for prediction of response to therapy; medical diagnostic testing services; genetic testing for medical for medical purposes; medical clinics; advice, information and consultancy services for all of the aforesaid services
Goods and ServicesScientific and technological services, namely, research and design in the field of psoriasis; medical research services; clinical research services, namely, conducting clinical trials for others; biological research; conducting clinical trials for others, namely, analysis, management and reporting of clinical data; consulting services in the field of quality assessment services for clinical laboratories; chemical research; chemical laboratory services; chemical analysis; scientific and medical laboratory services for analytical testing; medical laboratory services; biochemistry research and consultant advisory services; conducting clinical trials for others; providing computer aided diagnostic testing services for predicting response to anti-Tumor Necrosis Factor therapies for others in the field of science and research related thereto; scientific and technological services, namely, development of test equipment for medical apparatus for others; advice, information and consultancy services relating to all the aforesaid services

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 31, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 31, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 31, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 31, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRandox Laboratories Ltd
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCrumlin, Antrim BT294QY
GB

Party NameRandox Laboratories Ltd
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCrumlin, Antrim BT294QY
GB

Party NameRandox Laboratories Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCrumlin, Antrim BT294QY
GB

Trademark Events


Event DateEvent Description
Friday, March 31, 2023CANCELLED SEC. 8 (6-YR)
Monday, September 20, 2021COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, September 20, 2016REGISTERED-PRINCIPAL REGISTER
Monday, August 15, 20161(B) BASIS DELETED; PROCEED TO REGISTRATION
Monday, July 11, 2016NOTICE OF ALLOWANCE CANCELLED
Monday, July 11, 2016TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, December 29, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 28, 2015SOU EXTENSION 2 GRANTED
Thursday, December 17, 2015SOU EXTENSION 2 FILED
Thursday, December 17, 2015TEAS EXTENSION RECEIVED
Thursday, December 17, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 6, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 5, 2015SOU EXTENSION 1 GRANTED
Monday, July 20, 2015SOU EXTENSION 1 FILED
Wednesday, August 5, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 20, 2015TEAS EXTENSION RECEIVED
Tuesday, January 20, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 25, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 25, 2014PUBLISHED FOR OPPOSITION
Wednesday, November 5, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 22, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, October 22, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, October 6, 2014DATA MODIFICATION COMPLETED
Friday, October 3, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 3, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 3, 2014TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, May 19, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, May 19, 2014LETTER OF SUSPENSION E-MAILED
Monday, May 19, 2014SUSPENSION LETTER WRITTEN
Tuesday, May 6, 2014EXAMINER'S AMENDMENT ENTERED
Tuesday, May 6, 2014NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, May 6, 2014EXAMINERS AMENDMENT E-MAILED
Tuesday, May 6, 2014EXAMINERS AMENDMENT -WRITTEN
Thursday, May 1, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 1, 2014LETTER OF SUSPENSION E-MAILED
Thursday, May 1, 2014SUSPENSION LETTER WRITTEN
Tuesday, April 8, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 8, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 4, 2014ASSIGNED TO LIE
Tuesday, March 25, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 27, 2013NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 27, 2013NON-FINAL ACTION E-MAILED
Friday, September 27, 2013NON-FINAL ACTION WRITTEN
Tuesday, September 24, 2013ASSIGNED TO EXAMINER
Tuesday, June 25, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 18, 2013NEW APPLICATION ENTERED